“ICMR research exhibits Covaxin neutralises in opposition to a number of variants of SARS-CoV-2.”
Indigenously developed COVID-19 vaccine, Covaxin, neutralises a number of variants of SARS-CoV-2 and successfully works in opposition to the double mutant pressure as properly, the Indian Council of Medical Research (ICMR) stated on Wednesday.
Bharat Biotech’s Covaxin has acquired Emergency Use Authorizations (EUAs) for COVID-19 remedy in India and in a number of international locations throughout the globe with one other 60 within the course of.
“ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,” the ICMR tweeted.
Also learn | Bharat Biotech ramps up Covaxin manufacturing capability to 700 mn doses every year
ICMR-National Institute of Virology has efficiently remoted and cultured a number of variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant) and B.1.351 (South Africa variant).
ICMR-NIV has demonstrated the neutralisation potential of Covaxin in opposition to the UK variant and Brazil variant, the apex well being analysis physique stated.
ICMR-NIV lately has been profitable in isolating and culturing the double mutant pressure B.1.617 SARS-CoV-2 recognized in sure areas of India and a number of other different international locations, the ICMR acknowledged.
“Covaxin has been found to effectively neutralise the double mutant strain as well,” it stated.
